CURRICULUM VITAE

CHARLES KELLY NEWELL, M.D.

PERSONAL INFO:

Private Practice Group: Southern Vitreoretinal Associates, P.L. (July 1999-Present)
2439 Care Drive Tallahassee, FL 32308
(850) 942-6700 (800) 940-1225 Fax: (850) 942-5735

EDUCATION AND TRAINING:

College:	Florida State University Tallahassee, Florida BS in Biology, 1981-1985
	University of Tennessee, Department of Microbiology Knoxville, Tennessee MS in Microbiology, 1986-1989
Medical School:	University of Tennessee College of Medicine Memphis, Tennessee M.D., 1989-1993
Internship:	Baptist Memorial Hospital University of Tennessee Memphis, Tennessee, 1993-1994
Residency:	University of Florida Gainesville, FL, 1994-1997
Fellowship:	Retina and Vitreous Associates of Alabama Birmingham, Alabama, 1997-1999

MEDICAL LICENSURE:

Alabama #20826
Florida #ME0066977

BOARD CERTIFICATION:

Diplomate of the American Board of Ophthalmology, 2000

HONORS AND AWARDS:

- Physicians Medical Education and Research Foundation **(1990-1993)**
  Academic Scholarship, University of Tennessee College of Medicine

- National Cancer Institute Medical Student Research Scholarship, **(1990)**
  University of Miami, Bascom Palmer Eye Institute, Miami, Florida,

- Clinical Clerkships Evaluation Committee - elected by students **(1992-1993)**
  and faculty, University of Tennessee College of Medicine, Memphis, Tennessee,

TEACHING APPOINTMENTS:

- Clinical Assistant Professor, Florida State University School of Medicine **(2004 – present)**

MEMBERSHIPS:

- American Academy of Ophthalmology
- Florida Society of Ophthalmology
- American Medical Association
- American Society of Cataract and Refractive Surgeons

PAPER PRESENTATIONS:

Brooks H.L., Steinmetz R.L., Newell C.K. Repair of Retinal Detachment and Proliferative Vitreoretinopathy with and without Internal Limiting Membrane Peeling. Retina Congress, (the combined meeting of the Vitreous Society and the Retina Society). San Francisco, CA 2002.

Brooks H.L., Newell C.K., Steinmetz R.L., Fortin J., Caballero S., Grant M.B. Vitreous Levels of VEGF and SDF-1 in Patients with Diabetic Retinopathy. The ARVO Annual Meeting. Ft. Lauderdale, FL 2003. *Invest Ophthalmol Vis Sci* (suppl) (2003):178

Brooks H.L., Caballero S., Newell, C.K., Steinmetz R.L., Watson D., Grant MB. "Assessment of Triamcinolone Treatment for Neovascular Glaucoma". The ARVO Annual Meeting. Ft. Lauderdale, FL 2004. Invest Ophthalmol Vis Sci.

Brooks HL, Ashmore ED, Barker DL, Steinmetz RL, and Newell CK. "Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration, 2.5 mg vs 1.25 mg". The ARVO Annual Meeting. Ft. Lauderdale, FL. May 2006.

CLINICAL TRIALS:

Principal Investigator:

Verteporfin for Age-related Macular Degeneration Study. 2000.

COBALT Study. A Phase III, randomized, double-masked parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis compared with Lucentis monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD). 2008.

Roche. A Phase III, Multicenter, Randomized, Double-masked, Active Comparator-Controlled Study To Evaluate The Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema (YOSEMITE). 2018-2021.

F. Hoffman-La Roche. RHONE-X Extension, faricimab in DME, 2020-Present.

Apellis Pharmaceuticals. DERBY Phase III, sham-controlled study of safety & efficacy of APL-2 in GA secondary to AMD. 2019-Present.

Sub-Investigator:

Anecortave Acetate Study. Anecortave vs Visudyne therapy in patients with classic choroidal neovascularization. 2003-2005.

ANCHOR Study. rhuFab vs Visudyne therapy for patients with age-related macular degeneration. 2003-2005.

AART. An evaluation of efficacy and safety of posterior juxtascleral administrations of Anecortave Acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients (enrolled in Study "A" or Study "B") at risk for developing sight-threatening choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). 2004-2008.

Horizon Study. An open label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). 2006-2008.

BRAVO Study. Phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to BRVO. 2007.

CRUISE Study. Phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to CRVO. 2007.

CLINICAL TRIALS (CONTINUED)

Novartis Fingolimod Study. An arm of this study to observe participants with Multiple Sclerosis for Macular Edema while receiving treatment. 2007.

Ophthotech Corp. A Phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovistatm (anti PDGF-B pegylated aptamer) administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with subfoveal neovascular age-related macular degeneration. 2015.

Allergan. Safety and efficacy of Brimonidine posterior segment drug delivery system in patients with geographic atrophy secondary to age-related macular degeneration. 2015.

Alcon. A two-year, randomized, double-masked, multicenter, three arm study comparing the efficacy and safety of RTH258 versus Aflibercept in subject with neovascular age-related macular degeneration. 2015.

Roche. A Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration. 2015.

Regeneron. A randomized, double-masked, active-controlled Phase II study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration. 2016.

Roche. A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with diabetic macular edema. 2016.

Regeneron. A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy. 2017.

DigiSight Technologies, Inc. The Correlation of Paxos Checkup Mobile App to Standard In Office Visual Assessment (CLEAR). 2016 - Present.

Opthea. OPT 302-1002. A dose-ranging study of intravitreal OPT-302 combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD). 2018.

CLINICAL TRIALS (CONTINUED)

Clearside Biomedical. TOPAZ: A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal Anti-VEGF agent in subjects with retinal vein occlusion. 2018.

Roche. A Phase III, Multicenter, Randomized, Double-masked, Active Comparator-Controlled Study To Evaluate The Efficacy and Safety of FARICIMAB in Patients with Neovascular Age-Related Macular Degeneration (LUCERNE). 2019-Present.

Roche. A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients with Neovasular Age-related Macular Degeneration. 2019-Present.

Graybug Vision. A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wedt) Age-related Macular Degeneration (ALTISIMO Study). 2019.

Kodiak Sciences Inc. BEACON Phase III, Safety of KSI-301 compared to aflibercept in Macular Edema secondary RVO, 2020-Present.

Kodiak Sciences Inc. GLIMMER Phase III, Intravitreal KS1-301 vs. Aflibercept for visual impairment secondary to treatment-naïve DME, 2020-Present.

Genetech. GALLEGOLE Open-label Extension, FHTR2163 injections for GA secondary to AMD, 2020-Present.

F. Hoffman-La Roche. CAMINO Phase III, Faricimab for macular edema secondary to central retinal or hemiretinal vein occlusion, 2020-Present.

F. Hoffman-La Roche. BP41670 Phase I, RO7250284 multiple ascending doses vs. port delivery in neovascular AMD, 2020-present.

F. Hoffman-La Roche. PORTAL Extension, port delivery of Ranibizumab for neovascular AMD, 2020-Present.

F. Hoffman-La Roche. BALATON, Phase III, faricimab for macular edema secondary to branch RVO, 2020-Present.

F. Hoffmann-La Roche. PAVILION Phase III, Port delivery system with ranibizumab in PDR, 2020-Present.

CLINICAL TRIALS (CONTINUED)

F. Hoffman-La Roche Ltd. PAGODA Phase III, Port Delivery System with ranibizumab in DME, 2020-Present.

Regeneron Pharmaceuticals, Inc. CANDELA Phase II, High-Dose aflibercept in wet AMD, 2020-Present.

Iveric bio. GATHER2 Phase III, Zimura for GA secondary to dry AMD, 2020-Present.

Gemini Therapeutics. GEM-CL-10302 Phase II, Repeat intravitreal injections of GEM103 in GA secondary AMD, 2020-Present.

NGM Biopharmaceuticals. CATALINA, Phase II. Intravitreal NGM621for GA secondary to AMD, 2020-Present.

Aerie Pharmaceuticals, Inc. Phase I, AR-13503 Sustained Release Intravitreal Implant in DME, 2019-2021.

Genentech, Inc. GALLEGO Phase II, FHTR2163 in GA Secondary to AMD, 2019-2021.

F. Hoffman-La Roche Ltd. ARCHWAY Phase III, Port Delivery System with ranibizumab in wet AMD, 2018

PUBLICATIONS:

- Newell CK, Martin S, Sendele D, Rouse BT. Adoptive transfer of immune T-lymphocyte subsets and the effect on herpetic stromal keratitis. *Invest Ophthalmol Vis Sci.* 1989;30(suppl):S492.

- Newell CK, Martin S, Sendele D, Mercadal CM, Rouse BT. Herpes simplex virus-induced stromal keratitis: Role of T-lymphocyte subsets in immunopathology. *J Virol.* 1989;63:769-775.

- Newell CK, Sendele D, Rouse BT. Effects of CD4+ and CD8+ T-lymphocyte depletion on the induction and expression of herpes simplex stromal keratitis. *Reg Immunol.* 1989;2:366-369.

- Doymaz MZ, Newell CK, Rouse BT. Different roles of T-cell subsets in development of herpetic stromal keratitis (HSK). *FASEB J.* 1990; Vol. #7:A2223.

- Atherton SS, Newell CK, Kanter MY, Cousins SW. Necrotizing MCMV retinitis in T-cell depleted balb/c mice. International Herpes Virus Meeting 1990 (suppl). London, England.

- Atherton SS, Newell CK, Kanter MY, Cousins SW. T-cell depletion increases susceptibility to necrotizing retinitis following ocular inoculation of MCMV. *Invest Ophthalmol Vis Sci.* 1991 *(*suppl).

- Atherton SS, Newell CK, Kanter MY, Cousins SW. Retinitis in euthymic mice following inoculation of murine cytomegalovirus via the supraciliary route. *Curr. Eye 1*991;Research 10:667-677.

- Atherton SS, Newell CK, Kanter MY, Cousins SW. T-cell depletion increases susceptibility to MCMV retinitis. *Invest Ophthalmol Vis Sci*. 1992;33:3353-3360.

- Steinmetz, R.L., Brooks H.L., and Newell C.K. "Management of posteriorly dislocated posterior chamber intraocular lenses with vitrectomy and pars plana removal". *Retina* 2004;24:556-559

- HL Brooks, Jr. MD, CK Newell MD, RL Steinmetz MD, D Watson BS, CRA ,CDA, MS Segal MD, JK Harrison PhD, EW Scott PhD and MB Grant MD. "Vitreous levels of VEGF and SDF-1 in patients with diabetic retinopathy and cystoid macular Edema". *Arch Ophthalmol* 2004;122:1801-1807.

- Steinmetz R.L., Brooks H.L., and Newell C.K. "Management of posteriorly dislocated posterior chamber intraocular lenses with vitrectomy and pars plana removal". (Correspondence) *Retina*

- Newell CK, Steinmetz RL, Brooks HL Jr. "Chronic postoperative endophthalmitis caused by *Bipolaris Australiensis". Retina* 2006;26:109-110.